Fig. 3From: Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinomaThe difference in time to radiologic progression (a) and survival (b) after combination therapy of TACE and sorafenib according to HFSR-response in HCC patientsBack to article page